Alison C Tree

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4805270/publications.pdf

Version: 2024-02-01

24 813 11 23 papers citations h-index g-index

25 25 25 1055
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncology, The, 2019, 20, 1531-1543.	10.7	362
2	The MOMENTUM Study: An International Registry for the Evidence-Based Introduction of MR-Guided Adaptive Therapy. Frontiers in Oncology, 2020, 10, 1328.	2.8	81
3	Daily adaptive radiotherapy for patients with prostate cancer using a high field MR-linac: Initial clinical experiences and assessment of delivered doses compared to a C-arm linac. Clinical and Translational Radiation Oncology, 2020, 23, 35-42.	1.7	56
4	The Role of Hypofractionated Radiotherapy in Prostate Cancer. Current Oncology Reports, 2017, 19, 30.	4.0	50
5	Integrated MRI-guided radiotherapy — opportunities and challenges. Nature Reviews Clinical Oncology, 2022, 19, 458-470.	27.6	47
6	ESTRO-ACROP recommendations on the clinical implementation of hybrid MR-linac systems in radiation oncology. Radiotherapy and Oncology, 2021, 159, 146-154.	0.6	37
7	Patterns of Care, Tolerability, and Safety of the First Cohort of Patients Treated on a Novel High-Field MR-Linac Within the MOMENTUM Study: Initial Results From a Prospective Multi-Institutional Registry. International Journal of Radiation Oncology Biology Physics, 2021, 111, 867-875.	0.8	37
8	InÂVivo Validation of Elekta's Clarity Autoscan for Ultrasound-based Intrafraction Motion Estimation of the Prostate During Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 102, 912-921.	0.8	34
9	Daily Intravoxel Incoherent Motion (IVIM) In Prostate Cancer Patients During MR-Guided Radiotherapy—A Multicenter Study. Frontiers in Oncology, 2021, 11, 705964.	2.8	22
10	Patterns of recurrence after prostate bed radiotherapy. Radiotherapy and Oncology, 2019, 141, 174-180.	0.6	19
11	Longâ€ŧerm multicentre experience of adjuvant radiotherapy for pN3 squamous cell carcinoma of the penis. BJU International, 2021, 128, 451-459.	2.5	12
12	Feasibility of MR-guided ultrahypofractionated radiotherapy in 5, 2 or 1 fractions for prostate cancer. Clinical and Translational Radiation Oncology, 2021, 26, 1-7.	1.7	11
13	Trends in Management of Oligometastatic Hormone-Sensitive Prostate Cancer. Current Oncology Reports, 2019, 21, 43.	4.0	9
14	The Emerging Role of Local Therapy in Metastatic Prostate Cancer. Current Oncology Reports, 2020, 22, 2.	4.0	7
15	A narrative review of oligometastatic prostate cancer—an evolving paradigm. Annals of Palliative Medicine, 2021, 10, 57-57.	1.2	7
16	Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP Trial. International Journal of Radiation Oncology Biology Physics, 2022, 113, 305-315.	0.8	5
17	Magnetic Resonance Imaging–guided Adaptive Radiotherapy for Urological Cancers: What Urologists Should Know. European Urology, 2022, 82, 149-151.	1.9	5
18	Impact of centralization of prostate cancer services on the choice of radical treatment. BJU International, 2023, 131, 53-62.	2.5	4

ALISON C TREE

#	Article	IF	CITATIONS
19	Improving 3D ultrasound prostate localisation in radiotherapy through increased automation of interfraction matching. Radiotherapy and Oncology, 2020, 149, 134-141.	0.6	2
20	Intermediate clinical endpoints in localised prostate cancer. Lancet Oncology, The, 2021, 22, 294-296.	10.7	2
21	Longitudinal cohort analysis of patients with metastatic penile cancer treated in a large quaternary academic centre. Journal of Clinical Urology, 2023, 16, 293-302.	0.1	2
22	Single dose prostate radiotherapy â€" a step too far?. Nature Reviews Urology, 2021, 18, 445-446.	3.8	1
23	Efficacy and toxicity according to hormone therapy used in the CHHiP trial Journal of Clinical Oncology, 2020, 38, 316-316.	1.6	1
24	Optimal patient selection for stereotactic body radiotherapy – Authors' reply. Lancet Oncology, The, 2019, 20, e662.	10.7	0